Incidence of Urogenital Neoplasms in India

Satyanarayana Labani; Dishank Rawat; Smita Asthana

doi:10.4103/ijmpo.ijmpo_76_17

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(04): 446-451
DOI: 10.4103/ijmpo.ijmpo_76_17

Original Article

Incidence of Urogenital Neoplasms in India

Satyanarayana Labani

Division of Epidemiology and Biostatistics, Institute of Cytology and Preventive Oncology, Indian Council of Medical Research, Noida, Uttar Pradesh, India

,

Dishank Rawat

Division of Epidemiology and Biostatistics, Institute of Cytology and Preventive Oncology, Indian Council of Medical Research, Noida, Uttar Pradesh, India

,

Smita Asthana

Division of Epidemiology and Biostatistics, Institute of Cytology and Preventive Oncology, Indian Council of Medical Research, Noida, Uttar Pradesh, India

› Author Affiliations

Abstract

Objective: To study and compare the national and regional incidences and risk of developing of neoplasms of individual urogenital sites using 2012 – 2014 reports from the National Cancer Registry Programme (NCRP) data. Materials and Methods: A number of incident cases, age-adjusted rates (AARs), and cumulative risk (0 – 64 years) pertaining to urogenital neoplasms, along with the ICD-10 codes, were extracted. Data on indicators, namely number of incident cases, AARs and one in a number of persons develop cancer were summarized for both the sexes in each of the cancer registries and presented region-wise in the form of ranges. Results: The proportion of all urogenital neoplasms in comparison to all cancers was 12.51% in women and 5.93% in men. Risk of development of urogenital cancers for women was maximum (1 in 50) in the North-eastern region, followed by Rural West, South, and North. For men, the risk of developing neoplasms of urogenital sites was highest (1 in 250). For the neoplasms of the renal pelvis and ureter, both the incidence and risk were quite low for all genders across all the regions. Cervical neoplasms had the highest incidence (4.91 – 23.07) among female genital neoplasms, while prostate had the highest incidence (0.82 – 12.39) among male genital neoplasms. Conclusion: Making people aware of urogenital neoplasms and their risk factors are important for the public health awareness point of view. Centers that deal with either management of urogenital cases or/and screening of genital neoplasms could serve as the designated centers for creating such awareness.

Keywords

Age-adjusted rates - cancer registry - cumulative risk - incidence - neoplasms - urogenital

Full Text

References

References
1 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www.globocan.iarc.fr. [Last accessed on 2017 Mar 03].
2 Mattheij I, Pollock AM, Brhlikova P. Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness. J R Soc Med 2012; 105: 250-62
3 Krishnan S, Madsen E, Porterfield D, Varghese B. Advancing cervical cancer prevention in India: Implementation science priorities. Oncologist 2013; 18: 1285-97
4 Chawla PC, Chawla AK, Shrivastava R, Shrivastava A, Chaudhary S. Situation analysis of existing facilities for screening, treatment and prevention of cervical cancer in hospitals/primary health centers of Delhi-NCR region, India. Asian Pac J Cancer Prev 2014; 15: 5475-82
5 Raj S, Piang LK, Nair KS, Tiwari VK, Kaur H, Singh B. et al. Awareness regarding risk factors, symptoms and treatment facilities for cancer in selected states of India. Asian Pac J Cancer Prev 2012; 13: 4057-62
6 Rashid S, Labani S, Das BC. Knowledge, awareness and attitude on HPV, HPV vaccine and cervical cancer among the college students in India. PLoS One 2016; 11: e0166713
7 Wadhwa P. The current three-year postgraduate program in urology is insufficient to train urologists: Against the motion. Indian J Urol 2008; 24: 339-42
8 Letašiová S, Medve’ová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C. et al. Bladder cancer, a review of the environmental risk factors. Environ Health 2012; 11 (01) S11
9 Hemelt M, Yamamoto H, Cheng KK, Zeegers MP. The effect of smoking on the male excess of bladder cancer: A meta-analysis and geographical analyses. Int J Cancer 2009; 124: 412-9
10 Global Adult Tobacco Survey (GATS) India: 2009-2010. Mumbai: IIPS, Ministry of Health and Family Welfare, GOI; 2010. Available from: http://www.searo.who.int/LinkFiles/Regional_Tobacco_Surveillance_System_GATS_India.pdf. [Last accessed on 2017 Mar 29].
11 Asthana S, Chauhan S, Labani S. Breast and cervical cancer risk in India: An update. Indian J Public Health 2014; 58: 5-10
12 Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health 2014; 80: 412-7
13 Mishra GA, Pimple SA, Shastri SS. Prevention of cervix cancer in India. Oncology 2016; 91 (01) Suppl 1-7
14 Yeole BB. Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pac J Cancer Prev 2008; 9: 119-22
15 Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene 2014; 2: 596-605
16 Lalitha K, Suman G, Pruthvish S, Mathew A, Murthy NS. Estimation of time trends of incidence of prostate cancer – An Indian scenario. Asian Pac J Cancer Prev 2012; 13: 6245-50
17 WHO Document. Tobacco smoking. IARC Monographs on the Evaluation of the carcinogenic Risk of Chemicals to Humans. 38. Lyon: IARC; 1986. Available from: http://monographs.iarc.fr/ENG/Monographs/vol1-42/mono38.pdf. [Last accessed on 2017 Mar 03].
18 Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int J Cancer 2005; 114: 101-8